Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

<p>Analyses on circulating cytokines and leukocytes. <b>A,</b> Mean difference in peripheral cytokines (fold change) at cycle 1, cycle 2, and at presurgery evaluation between patients with MPR (<i>n</i> = 11) and without MPR (<i>n</i> = 25). <b>B,</...

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Maria Alsina (21718246) (author)
Drugi avtorji:	Guillermo Villacampa (17098997) (author), Carlos de Andrea (14962659) (author), Ana Vivancos (15050228) (author), Mariano Ponz-Sarvise (14936295) (author), Virginia Arrazubi (21718249) (author), Paula Jimenez-Fonseca (15017523) (author), Marc Diez (21718252) (author), Enrique Sanz-Garcia (17990215) (author), Eva Martínez (21718255) (author), Raquel Guardeño (21718258) (author), Mariona Calvo (21718261) (author), Cristina Bugés (21718264) (author), Federico Longo (19135443) (author), Víctor Navarro (21718267) (author), Eduardo García-Galea (21234164) (author), Alena Gros (15056563) (author), Maria C. Ochoa (15031017) (author), Alvaro Lopez-Janeiro (21718270) (author), Sandra Sanchez-Gregorio (19663285) (author), Claudia Herrero (21718273) (author), Ibone Labiano (21718276) (author), Maria Vila-Casadesús (15050192) (author), Dario López (21718279) (author), Raluca Alexandru (21718282) (author), Susana Muñoz (21718285) (author), Josep Tabernero (13744966) (author), Ignacio Melero (14962701) (author)
Izdano:	2025
Teme:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Biomarkers Prognostic biomarkers Clinical Trial Results Phase II clinical trials Gastrointestinal Cancers Stomach cancer Immunotherapy Checkpoint blockade Translational Research
Oznake:	Označite Brez oznak, prvi označite!